Unlocking Pipeline Strategy: What a Decade of Modality Data Reveals

The drug modality toolkit has expanded significantly in the past 10 years.

The choice of modalities is not just a science question, it shapes pipeline strategy, dealmaking and competitive edge.

Small molecules remain the largest marketed base, but the pipeline is packed with advanced modalities driving innovation. Where will cell and gene therapies, antibodies, and RNA therapies have the most impact?

Share:

Register today








About this webinar

Evaluate’s consultants will walk through a decade of data to demonstrate how antibodies, cell therapies and DNA and RNA therapies have grown, where they concentrate by therapy area, and what recent deals say about where big pharma expects the next wave of approvals.

Join us to learn which modalities are gaining ground in specific therapy areas, and where the pipeline is headed in the coming years.

The session will answer:

  • Why do ADC and multispecific deals keep climbing when about 82% of those assets are still in Phase I-II?
  • Which modalities are taking hold in oncology, CVRM, immunology and inflammation, and neuroscience?
  • Where are nucleic acid and cell therapies moving beyond their original areas?
  • What do today’s pipeline and marketed mixes suggest the market will look like in five to ten years?
  • Which signals, from Phase III readouts to safety warnings, are shaping investment?

Speakers

Pengfei Lu

Senior Manager, Consulting & Analytics

Tiffany Chan

Manager, Consulting & Analytics
Sofia Petta, Senior Consultant, Consulting & Analytics

Sofia Petta

Senior Consultant, Consulting & Analytics

Frequently Asked Questions

The toolkit for drug development has expanded rapidly over the past decade. Antibody, cell, gene and DNA and RNA products have each more than tripled since 2016. Choosing a modality now shapes a company’s pipeline, BD&L strategy and competitive position, as well as the science.

All analyses use Norstella proprietary databases, including Evaluate Pharma, Trialtrove and Pharmaprojects, extracted in August 2026 and covering 2016 to 2026. Trial analyses cover industry-sponsored Phase I-III studies. Products are new molecular entities only, with no biosimilars or generics, counted at program level.

The session covers antibodies (including ADCs and multispecifics), DNA and RNA therapies, and cell therapies. It looks at oncology, CVRM, immunology and inflammation, and neuroscience in detail.

Anyone who needs a clear, data-backed view of where R&D investment is heading to inform pipeline, partnership, competitive or investment decisions.

A structured view of how modality mix has shifted since 2016, where each modality is concentrated by therapy area, and the deals and trial readouts to watch next.

Explore all webinars